Essential Hypertension
Conditions
Keywords
Fimasartan, Essential Hypertension
Brief summary
Study objective: 1. To evaluate the antihypertensive efficacy, safety and tolerability of the drug after the oral administration of BR-A-657•K at 20\ 180mg for 4 weeks to patients with essential hypertension. 2. To review the pharmacokinetic profile after the multiple administration and the pharmacodynamic profile regarding the renin-angiotensin system, after the oral administration of BR-A-657•K at 20\ 180mg for 4 weeks to patients with essential hypertension. 3. To determine the dose for the clinical study at the next phase by analyzing the relationship between the antihypertensive efficacy and pharmacokinetic • pharmacodynamic results.
Detailed description
Fimasartan (BR-A-657-K), a selective blocker of AT1 receptor subtype, showed the rapid and potent antihypertensive effect in many hypertensive models. Phase I study, Fimasartan (BR-A-657-K) 20mg \ 480mg single dosing with healthy subjects, demonstrated that the Fimasartan (BR-A-657-K) was very safe and well tolerated. Another phase I study, Fimasartan (BR-A-657-K) 120mg and 360mg dosing for 7 days, also showed that Fimasartan (BR-A-657-K) was safe and tolerable though one temporal adverse event was observed in high dose. A randomized, double-blind, placebo-controlled, parallel grouped, clinical study will be conducted to evaluate the antihypertensive efficacy and tolerability and to determine adequate antihypertensive dosage of Fimasartan(BR-A-657-K) in patients with mild to moderate essential hypertension. Approximately 60 patients will be enrolled over 12 months in Seoul National University Hospital. After 2 weeks of placebo run-in period, all subjects will be randomized into one of the following 5 groups. Subjects will take test drug/placebo for 28 days of treatment period. If subjects take any antihypertensive medications before screening, the subjects will have 1 week of wash-out period. Group I : Placebo, Group II : Fimasartan 20 mg, Group III: Fimasartan 60 mg, Group IV : Fimasartan 180 mg
Interventions
DRUGPlacebo
Placebo
DRUGFimasartan (BR-A-657•K) 20 mg
Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
DRUGFimasartan (BR-A-657•K) 60 mg
Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
DRUGFimasartan (BR-A-657•K) 180 mg
Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Adult men and women, aged 18 - 65 * Patients with mild to moderate essential hypertension: On both screening and Day -1 visit, mean sitting DBP should be ≥ 95mmHg and ≤ 114mmHg, and ΔDBP on Day -14 and Day -1 should be within 7 mmHg * Patients who gave their consent to participate in this study and signed the written informed consent form * Patients who have understood the study, and been judged to be cooperative and able to participate in the study until the study completion date
Exclusion criteria
1. Women of childbearing potential who have not received the hysterectomy or men who are not willing to use birth control measures. 2. Patients whose sitting DBP is \< 95mmHg or ≥ 115mmHg. Patients with severe hypertension whose SBP is ≥200mmHg 3. Patients with secondary hypertension 4. Patients with severe renal disease, gastrointestinal disorder, hematologic disorder, liver disease, etc. that can affect the absorption, distribution, metabolism and excretion of drugs 5. Patients with symptoms of orthostatic hypotension 6. Patients with severe insulin dependent diabetes or uncontrolled diabetes 7. Patients who suffered myocardial infarction or serious coronary arterial disease over the past 6 months or patients with clinically significant congestive heart failure or valvular heart disease 8. Patients with consumption disease, autoimmune disease, or connective tissue disease 9. Patients with the history of type B hepatitis or type C hepatitis 10. Patients with HIV infection or hepatitis 11. Patients with clinically significant abnormal laboratory test findings 12. Patients on any drug treatment that might affect the blood pressure 13. Patients with allergy or contraindication to angiotensin II-receptor antagonists 14. Patients with current or suspected alcohol addiction or history of drug abuse 15. Patients whose mean weight lies out of the range of -15% \ +35%, based on the Modified Metropolitan Life Insurance table 16. Patients who are not eligible as subjects of the study, as determined by the principal investigator or a sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the level of sitting diastolic blood pressure reduction | Day -1 vs Day 27 |
Secondary
| Measure | Time frame |
|---|---|
| the level of sitting systolic blood pressure reduction, mean blood pressure (MBP), 24-hr day-time, night-time SBP and DBP, T/P ratio based on the 24-hr Ambulatory Blood Pressure Monitoring | Day -1 vs Day 27 |
Outcome results
None listed